Shares of Omnicell, Inc. (NASDAQ:OMCL – Get Free Report) have received a consensus recommendation of “Hold” from the six research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $42.20.
OMCL has been the topic of several recent analyst reports. Wells Fargo & Company cut their target price on shares of Omnicell from $28.00 to $26.00 and set an “equal weight” rating on the stock in a research note on Friday. Piper Sandler raised shares of Omnicell from a “neutral” rating to an “overweight” rating and cut their target price for the company from $70.00 to $39.00 in a research note on Friday, November 3rd. Barclays started coverage on shares of Omnicell in a research note on Wednesday, January 3rd. They issued an “underweight” rating and a $33.00 price target on the stock. Benchmark dropped their price target on shares of Omnicell from $42.00 to $38.00 and set a “buy” rating on the stock in a research note on Friday. Finally, TheStreet downgraded shares of Omnicell from a “c-” rating to a “d+” rating in a research note on Tuesday, October 24th.
Institutional Investors Weigh In On Omnicell
Omnicell Price Performance
Shares of NASDAQ:OMCL opened at $28.90 on Thursday. The company’s fifty day moving average is $34.84 and its two-hundred day moving average is $42.71. The company has a quick ratio of 2.22, a current ratio of 2.52 and a debt-to-equity ratio of 0.48. Omnicell has a 12-month low of $26.66 and a 12-month high of $77.14. The company has a market cap of $1.31 billion, a P/E ratio of -64.22 and a beta of 0.83.
Omnicell Company Profile
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
- Five stocks we like better than Omnicell
- How to Invest in Cannabis, Step by Step
- 3 attractive stocks that insiders are buying
- 3 Best Fintech Stocks for a Portfolio Boost
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.